Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

DSpace/Manakin Repository

Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Citable link to this page

 

 
Title: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma
Author: Rini, Brian I.; McDermott, David F.; Hammers, Hans; Bro, William; Bukowski, Ronald M.; Faba, Bernard; Faba, Jo; Figlin, Robert A.; Hutson, Thomas; Jonasch, Eric; Joseph, Richard W.; Leibovich, Bradley C.; Olencki, Thomas; Pantuck, Allan J.; Quinn, David I.; Seery, Virginia; Voss, Martin H.; Wood, Christopher G.; Wood, Laura S.; Atkins, Michael B.

Note: Order does not necessarily reflect citation order of authors.

Citation: Rini, B. I., D. F. McDermott, H. Hammers, W. Bro, R. M. Bukowski, B. Faba, J. Faba, et al. 2016. “Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.” Journal for Immunotherapy of Cancer 4 (1): 81. doi:10.1186/s40425-016-0180-7. http://dx.doi.org/10.1186/s40425-016-0180-7.
Full Text & Related Files:
Abstract: Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number of new agents have been approved for RCC, several of which attack tumor angiogenesis by inhibiting vascular endothelial growth factors (VEGF) and VEGF receptors (VEGFR), as well as tumor metabolism, inhibiting the mammalian target of rapamycin (mTOR). Additionally, a new class of immunotherapy agents, immune checkpoint inhibitors, is emerging and will play a significant role in the treatment of patients with RCC. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a Task Force, which met to consider the current role of approved immunotherapy agents in RCC, to provide guidance to practicing clinicians by developing consensus recommendations and to set the stage for future immunotherapeutic developments in RCC. Electronic supplementary material The online version of this article (doi:10.1186/s40425-016-0180-7) contains supplementary material, which is available to authorized users.
Published Version: doi:10.1186/s40425-016-0180-7
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109802/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:29626006
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters